Get Live Data

The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Skinbiotherap. Share Price
  4. Skinbiotherap. Share Regulatory News
  5. Investor Presentation – Interim Financial Results

Pin to quick picksSkinbiotherap. Regulatory News (SBTX)

Skinbiotherap. Information

Share Price Information for Skinbiotherap. (SBTX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (5.556%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.25
SBTX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investor Presentation – Interim Financial Results

22 Mar 2022 14:00

RNS Number : 6051F
SkinBioTherapeutics PLC
22 March 2022
 

22 March 2022

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Investor Presentation - Interim Financial Results

 

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that Stuart Ashman, CEO, & Doug Quinn, CFO, will provide an update to investors on the Company's interim financial results via the Investor Meet Company platform on 29th March 2022 at 09:00am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet SkinBioTherapeutics plc via:

https://www.investormeetcompany.com/skinbiotherapeutics-plc/register-investor

Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.

 

For more information please contact:

SkinBioTherapeutics plc

Stuart J. Ashman, CEO

Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson, Dale Bellis (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Nathan Billis

Tel: +44 (0) 20 7457 2020

SkinBio@instinctif.com

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAPPUQAWUPPGUP
12345
Date   Source Headline
4th Jan 20231:33 pmRNSResult of General Meeting
30th Dec 202211:33 amRNSResults of AGM
23rd Dec 20227:00 amRNSReport and Accounts, and Provision Update
21st Dec 20227:00 amRNSResult of Retail Offer
19th Dec 202211:15 amEQSSkinBioTherapeutics will 'continue to be flexible enough to adapt to opportunities'
16th Dec 20227:00 amRNSResult of Placing
15th Dec 20224:32 pmRNSREX Retail Offer
15th Dec 20224:31 pmRNSPlacing and REX Retail Offer
15th Dec 20224:30 pmRNSFinal Results
6th Dec 20227:40 amRNSNotice of AGM
31st Aug 20222:05 pmRNSSecond Price Monitoring Extn
31st Aug 20222:00 pmRNSPrice Monitoring Extension
31st Aug 20227:00 amRNSUpdate of oral programme and trading
22nd Aug 20229:05 amRNSSecond Price Monitoring Extn
22nd Aug 20229:00 amRNSPrice Monitoring Extension
27th Jul 20224:41 pmRNSSecond Price Monitoring Extn
27th Jul 20224:36 pmRNSPrice Monitoring Extension
27th Jul 20222:05 pmRNSSecond Price Monitoring Extn
27th Jul 20222:00 pmRNSPrice Monitoring Extension
13th Jun 20223:37 pmRNSStmnt re Share Price Movement
13th Jun 202211:05 amRNSSecond Price Monitoring Extn
13th Jun 202211:00 amRNSPrice Monitoring Extension
26th May 20222:02 pmRNSChange of Registered Office
27th Apr 20227:00 amRNSConfirmation of Directorate Appointments
29th Mar 202211:05 amRNSSecond Price Monitoring Extn
29th Mar 202211:00 amRNSPrice Monitoring Extension
29th Mar 20227:00 amRNSHalf-year Report
28th Mar 20227:00 amRNSDirectorate Change
22nd Mar 20222:00 pmRNSInvestor Presentation – Interim Financial Results
16th Mar 20227:00 amRNSNotice of Results
17th Feb 20227:00 amRNSBusiness update
8th Feb 202211:20 amRNSHolding(s) in Company
18th Jan 20227:00 amRNSDirectorate Change
12th Jan 20227:00 amRNSGrant of share options
23rd Dec 20212:00 pmRNSResult of AGM
21st Dec 20212:00 pmRNSAnnual General Meeting 2021 – Change of Venue
14th Dec 20217:00 amRNSHolding(s) in Company
6th Dec 20212:05 pmRNSSecond Price Monitoring Extn
6th Dec 20212:00 pmRNSPrice Monitoring Extension
30th Nov 20214:41 pmRNSSecond Price Monitoring Extn
30th Nov 20214:36 pmRNSPrice Monitoring Extension
30th Nov 20212:05 pmRNSSecond Price Monitoring Extn
30th Nov 20212:00 pmRNSPrice Monitoring Extension
30th Nov 202111:06 amRNSSecond Price Monitoring Extn
30th Nov 202111:00 amRNSPrice Monitoring Extension
30th Nov 20217:00 amRNSFull year results
26th Nov 20214:12 pmRNSNotice of Results
15th Nov 20214:59 pmRNSHolding(s) in Company
15th Nov 20217:00 amRNSPlacing of Shares
29th Oct 20214:40 pmRNSSecond Price Monitoring Extn
12345

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.